Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma - Centre Henri Becquerel
Journal Articles Haematologica Year : 2024

Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma

Abstract

Not available.

Domains

Cancer Methods and statistics Statistics [stat] Other Statistics [stat.ML] Methodology [stat.ME]
Fichier principal
Vignette du fichier
2024_Pages_Haematologica.pdf (2.05 Mo) Télécharger le fichier
Origin Publication funded by an institution
licence
Attribution - NonCommercial

Camille Dumont  : Connect in order to contact the contributor

https://inserm.hal.science/inserm-04671855

Submitted on : Friday, August 16, 2024-3:24:16 PM

Last modification on : Tuesday, October 8, 2024-6:40:27 PM

Download

Dates and versions

inserm-04671855 , version 1 (16-08-2024)

Licence

Attribution - NonCommercial

Identifiers

Cite

Loic Renaud, Juliette Wencel, Arnaud Pagès, Ahmad Al Jijakli, Hannah Moatti, et al.. Nivolumab combined with brentuximab vedotin with or without mediastinal radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma. Haematologica, 2024, ⟨10.3324/haematol.2023.284689⟩. ⟨inserm-04671855⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM CNRS CESP FNCLCC BECQUEREL UVSQ COMUE-NORMANDIE UNIV-PARIS-SACLAY UNIROUEN UP-SANTE GS-SANTE-PUBLIQUE ONCOSTAT
119 View
25 Download

Altmetric

Share

More